Display options
Cite
Ng SP, Duchesne G, Tai KH, et al. Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients. Prostate Int. 2016;5(1):8-12doi: 10.1016/j.prnil.2016.12.001.
Ng, S. P., Duchesne, G., Tai, K. H., Foroudi, F., Kothari, G., & Williams, S. (2017). Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients. Prostate international, 5(1), 8-12. https://doi.org/10.1016/j.prnil.2016.12.001
Ng, Sweet Ping, et al. "Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients." Prostate international vol. 5,1 (2017): 8-12. doi: https://doi.org/10.1016/j.prnil.2016.12.001
Ng SP, Duchesne G, Tai KH, Foroudi F, Kothari G, Williams S. Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients. Prostate Int. 2017 Mar;5(1):8-12. doi: 10.1016/j.prnil.2016.12.001. Epub 2016 Dec 18. PMID: 28352617; PMCID: PMC5357856.
Copy Download .nbib Format: NLM
Share it on

Prostate Int. 2017 Mar;5(1):8-12. doi: 10.1016/j.prnil.2016.12.001. Epub 2016 Dec 18.

Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients.

Prostate international

Sweet Ping Ng, Gillian Duchesne, Keen-Hun Tai, Farshad Foroudi, Gargi Kothari, Scott Williams

Affiliations

  1. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  2. Department of Radiation Oncology, Austin Health, Melbourne, Australia.

PMID: 28352617 PMCID: PMC5357856 DOI: 10.1016/j.prnil.2016.12.001

Abstract

BACKGROUND: Prostate cancer management involves a balance between the risks of cancer death against those from other causes. To evaluate the performance of several comorbidity indices in predicting comorbid death in a prostate cancer radiotherapy cohort.

METHODS: 2,131 men with localised prostate cancer treated with radical radiotherapy between 1999 and 2007 were studied. Tumour features, androgen deprivation usage, age, number of prescription medications (PMN) and Adult Comorbidity Evaluation-27 Index (ACE-27) were recorded. Death from prostate cancer (DPC) and death from other causes (DOC) were analysed as competing causes of death using a competing risks model, with discrimination assessed using the concordance index.

RESULTS: ACE-27 scores correlated with patient's PMN (median PMN = 2). Tumour features were independent of ACE-27 scores. Estimated cumulative incidences of DOC and DPC at 10 years were 16.4% and 7.7% respectively. In the low/intermediate risk group (

CONCLUSION: Age, ACE-27 score and PMN act as independent prognostic factors for DOC in prostate cancer patients and can improve patient's life expectancy prediction.

Keywords: Comorbidity; Prostate cancer; Radiotherapy

References

  1. J Clin Oncol. 2011 Jun 1;29(16):2240-6 - PubMed
  2. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1293-301 - PubMed
  3. Biometrics. 2011 Mar;67(1):39-49 - PubMed
  4. Cancer. 2007 May 1;109(9):1777-83 - PubMed
  5. BJU Int. 2007 Dec;100(6):1254-8 - PubMed
  6. J Clin Epidemiol. 2011 Feb;64(2):223-8 - PubMed
  7. J Clin Oncol. 2009 Dec 10;27(35):6000-5 - PubMed
  8. J Clin Oncol. 2011 Apr 1;29(10):1335-41 - PubMed
  9. JAMA. 1998 Sep 16;280(11):975-80 - PubMed
  10. Arch Intern Med. 2010 Aug 9;170(15):1396-7 - PubMed
  11. JAMA. 2000 Jun 28;283(24):3217-22 - PubMed
  12. Cancer. 2011 May 15;117(10):2058-66 - PubMed
  13. J Clin Oncol. 2003 Sep 1;21(17):3318-27 - PubMed
  14. BJU Int. 2001 Jun;87(9):821-6 - PubMed
  15. N Engl J Med. 2011 Jul 14;365(2):169-71 - PubMed
  16. Aust N Z J Public Health. 2009 Apr;33(2):126-30 - PubMed
  17. Stat Med. 1990 Jul;9(7):777-84 - PubMed
  18. Urology. 2002 Aug;60(2):258-63 - PubMed

Publication Types